Publications

Africa Guidelines for Hepatocellular Carcinoma Buildup Process

Abou-Alfa GK, Afihene M, Capanu M, Li Y, Chou JF, Asombang A, Alatise OI, Bounedjar A, et al.

Alliance A021804: A prospective, multi-institutional phase II trial evaluating temozolomide versus temozolomide and olaparib for advanced pheochromocytoma and paraganglioma.

J Del Rivero, K Perez, SM Geyer, MF Khalil, A Vijendran, ...

Alliance A021806: A phase III trial evaluating perioperative versus adjuvant therapy for resectable pancreatic cancer.

A Chawla, Q Shi, AH Ko, S Beg, AM Varghese, SW Behrman, ...

Alliance A022101: A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer–Evaluating Radiation, Ablation …

PB Romesser, ED Miller, Q Shi, JG Dixon, S Gholami, S White, C Wu, ...

Alliance A022104/NRG-GI010: A randomized phase II trial testing the efficacy of triplet versus doublet chemotherapy to achieve clinical complete response in patients with …

JJ Smith, A Dasari, Q Shi, J Garcia-Aguilar, HK Sanoff, TJ George, ...

AMPLIFY-201, a first-in-human safety and efficacy trial of adjuvant ELI-002 2P immunotherapy for patients with high-relapse risk with KRAS G12D-or G12R-mutated pancreatic and …

EM O'Reilly, ZA Wainberg, CD Weekes, M Furqan, PM Kasi, CE Devoe, ...

Apollo: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1 …

KA Reiss, SC Hong, A Kasi, EM O'Reilly, SK Maithel, X Yao, SR Hamilton, ...

Association between physical activity and the time course of cancer recurrence in stage III colon cancer

Brown JC, Ma C, Shi Q, Niedzwiecki D, Zemla T, Couture F, Kuebler P, Kumar P, et al.

Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer

Nasca V, Barretta F, Corti F, Lonardi S, Niger M, Elez ME, Fakih M, Jayachandran P, et al.

Association of inflammatory biomarkers with survival among patients with stage III colon cancer

E Cheng, Q Shi, AF Shields, AB Nixon, AP Shergill, C Ma, KA Guthrie, ...

Atezolizumab plus PEGPH20 versus chemotherapy in advanced pancreatic ductal adenocarcinoma and gastric cancer: MORPHEUS phase Ib/II umbrella randomized study platform

AH Ko, KP Kim, JT Siveke, CD Lopez, J Lacy, EM O’Reilly, T Macarulla, ...

Biospecimen Repositories in Low- and Middle-Income Countries: Insights From an American University of Beirut and Memorial Sloan Kettering Collaboration

Faraj W, Robson M, Tawil A, Reuter V, Mahfouz R, Cambria R, Saheb N, Ferrer CS, et al.

Cancer genetic mutation prevalence in sub-Saharan Africa: A review of existing data

Shain J, Michel A, May MS, Qunaj L, El-Sadr W, Chung WK, Appelbaum PS, Jacobson JS, et al.

Clinical and molecular characterization of microsatellite stable (MSS) tumors in patients with Lynch syndrome (LS).

E Harrold, C Vanderbilt, A Maio, M Borio, M Ranganathan, M Sheehan, ...

Clinical benefit of granulocyte-colony stimulating factor (GCSF) use during chemoimmunotherapy treatment for metastatic pancreatic adenocarcinoma (mPDAC).

JP Lyman, CR Cabanski, S Maddock, RA Wolff, ZA Wainberg, AH Ko, ...

Clinical outcomes for IDH1 mutant biliary tract cancer (BTC) treated with contemporary systemic therapy.

D Cowzer, R Huq, M Perry, F Keane, W Park, IH El Dika, D Khalil, J Shia, ...

Clinical utility of next generation sequencing (NGS) on circulating tumor DNA (ctDNA) in patients (pts) with pancreatic cancer (PC).

F Keane, L Saadat, C O'Connor, JF Chou, AR Brannon, D Cowzer, ...

Consensus statement on the surveillance of patients with gastrointestinal malignancies

F Keane, M Greally, A Horgan, K Duffy, M Lowery, P Martin, L Grogan, ...

Dietary fat in relation to all‐cause mortality and cancer progression and death among people with metastatic colorectal cancer: Data from CALGB 80405 (Alliance)/SWOG 80405

EL Van Blarigan, C Ma, FS Ou, TM Bainter, AP Venook, K Ng, ...

Does acute pancreatitis herald pancreatic ductal adenocarcinoma? A multicenter electronic health research network study

Singh RR, Klein AP, Sharma NR, O'Reilly EM

Dramatic, durable response to therapy in gBRCA2-mutated pancreas neuroendocrine carcinoma: opportunity and challenge

Keane F, Bajwa R, Selenica P, Park W, Roehrl MH, Reis-Filho JS, Mandelker D, O'Reilly EM

Durable Response after Olaparib Treatment for Perihilar Cholangiocarcinoma with Germline BRCA2 Mutation

Costa BA, Tallón de Lara P, Park W, Keane F, Harding JJ, Khalil DN

Evaluation of microsatellite instability status, a definitive predictive biomarker for immune checkpoint inhibitors (ICI), in underrepresented minorities (URM) with …

F Balogun, M Altoe, C O'Connor, N Chowdhury, A Cercek, C Lee, ...

Favorable Survival after Definitive Ablative RT in Surgically Resectable Pancreatic Cancer Patients

M Reyngold, E O'Reilly, M Zinovoy, C Hajj, AJ Wu, J Cuaron, ...

Flashback Foreword: Bevacizumab and FOLFOX4 for Colorectal Cancer and Bevacizumab Versus Placebo Plus Oxaliplatin-Based Chemotherapy in Metastatic Colorectal Cancer

O'Reilly EM

Flashback foreword: gemcitabine for advanced pancreatic cancer

EM O'Reilly, AH Ko, JW Friedberg

FRONTIER: FAPi radioligand open-label, phase 1 study to evaluate safety, tolerability and dosimetry of [Lu-177]-PNT6555—A dose escalation study for treatment of patients with …

L Bodei, P Kavan, M Liberman, N Taunk, U Metser, D Juneau, EM O'Reilly, ...

Genetics, structure, transmission, epidemiology, immune response, and vaccine efficacies of the SARS-CoV-2 Delta variant: A comprehensive review

Li H, Arcalas CJ, Song J, Rahmati M, Park S, Koyanagi A, Lee SW, Yon DK, et al.

Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized Pancreatic Ductal Adenocarcinoma

Ecker BL, Tao AJ, Janssen QP, Walch HS, Court CM, Balachandran VP, Crane CH, D'Angelica MI, et al.

Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized Pancreatic Ductal Adenocarcinoma

AJ Tao, BL Ecker, Q Janssen, VP Balachandran, MI D'Angelica, JA Drebin, ...

Genomic Profiling Reveals Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell Carcinoma

Mandelker D, Marra A, Zheng-Lin B, Selenica P, Blanco-Heredia J, Zhu Y, Gazzo A, Wong D, et al.

Immune Strategies for Gastrointestinal

JJ Harding, EM O'Reilly

Immune Strategies for Gastrointestinal Cancer: HCC

DN Khalil, I El Dika, H Azhari, JJ Harding, EM O’Reilly, GK Abou-Alfa

KRAS(G12D) inhibition in pancreatic cancer: Fas expression facilitates immune clearance

Yeh C, Park W, Yaeger R

LBA53 Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET)

J Chan, S Geyer, FS Ou, M Knopp, S Behr, T Zemla, J Acoba, A Shergill, ...

Liposomal irinotecan+ 5-fluorouracil/leucovorin+ oxaliplatin (NALIRIFOX) versus nab-paclitaxel+ gemcitabine in treatment-naive patients with metastatic pancreatic ductal …

EM O'Reilly, D Melisi, T Macarulla, RA Pazo Cid, SR Chandana, ...

Metastatic well differentiated serotonin-producing pancreatic neuroendocrine tumor with carcinoid heart disease: a case report

MR Kudelka, GK Abou-Alfa, EM O’Reilly, MB Foote, B Sirohi, R Elias, ...

Molecular profiles and single cell analysis identify immunogenic pancreatic ductal adenocarcinoma (iPDAC)

W Park, C O'Connor, S Umeda, R Sharma, Y Zhu, ER Karnoub, ...

NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial

ZA Wainberg, D Melisi, T Macarulla, RP Cid, SR Chandana, ...

NAPOLI-3: A randomized, open-label Phase 3 study of liposomal irinotecan+ 5-fluorouracil/leucovorin plus oxaliplatin (NALIRIFOX) versus nab-paclitaxel plus gemcitabine in …

T Goetze, D Melisi, T Macarulla, AR Pazo Cid, RS Chandana, ...

NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan+ 5-fluorouracil/leucovorin+ oxaliplatin (NALIRIFOX) versus nab-paclitaxel+ gemcitabine in treatment …

ZA Wainberg, D Melisi, T Macarulla, R Pazo-Cid, SR Chandana, ...

NAPOLI-3: A randomized, open-label Phase 3 study of liposomal irinotecan+ 5-fluorouracil/leucovorin+ oxaliplatin (NALIRIFOX) versus nab-paclitaxel+ gemcitabine in treatment …

T Goetze, D Melisi, T Macarulla, R A Pazo Cid, S R Chandana, ...

Neoplasia risk in patients with Lynch syndrome treated with immune checkpoint blockade

EC Harrold, MB Foote, B Rousseau, H Walch, Y Kemel, AL Richards, ...

O-1 Liposomal irinotecan+ 5-fluorouracil/leucovorin+ oxaliplatin (NALIRIFOX) versus nab-paclitaxel+ gemcitabine in treatment-naive patients with metastatic pancreatic ductal …

Z Wainberg, D Melisi, T Macarulla, RP Cid, S Chandana, ...

Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade

Randon G, Aoki Y, Cohen R, Provenzano L, Nasca V, Klempner SJ, Maron SB, Cerantola R, et al.

P-190 NALIRIFOX (iposomal irinotecan+ 5-fluorouracil/feucovorin+ oxaliplatin) versus FOLFOX [5-fluorouracil/leucovorin+ oxaliplatin] as first-line treatment of metastatic …

E O'Reilly, J Li, M DerSarkissian, R Chang, M Cheng, L Yu, D Rane, ...

P-266 Outcomes in advanced hepatocellular carcinoma (HCC) patients (pts) treated with immune checkpoint inhibitors (ICI)

D Cowzer, M Capanu, F Keane, D Khalil, J Shia, R Do, J Chou, H Walch, ...

P-272 Patients (pts) with advanced hepatocellular carcinoma (HCC) with long-term response to immune checkpoint inhibitor (ICI) therapy

F Keane, D Cowzer, D Khalil, J Shia, R Do, S Folorunso, I El Dika, ...

Pancreatic Cancer: BRCA Targeted Therapy and Beyond

Keane F, O'Connor CA, Park W, Seufferlein T, O'Reilly EM

Pancreatic cancer: Cutaneous metastases, clinical descriptors and outcomes

Gu L, Mehta PP, Rao D, Rotemberg V, Capanu M, Chou J, Lin S, Sigel CS, et al.